2016
DOI: 10.1111/cen.13129
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: SummaryObjective Growth hormone (GH) and insulin-like growth factor I (IGF-I) are the principal biomarkers used to assess disease activity in acromegaly, and any discrepancy between them renders interpretation of results inconclusive. Purpose of this study was to assess the frequency of this discrepancy and identify parameters that might affect its occurrence. Design A systematic review of MEDLINE and Scopus was performed followed by a meta-analysis to address the frequency of discrepant results between GH an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
22
0
1

Year Published

2017
2017
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 27 publications
(25 citation statements)
references
References 32 publications
2
22
0
1
Order By: Relevance
“…Our observation of high GH levels as the most prevalent discordance is in agreement with some (10) but not all studies (7,18). It is, however, problematic to compare discordant values between studies due to pronounced heterogeneity as regards patient populations, GH assays and threshold definitions.…”
Section: Discussionsupporting
confidence: 89%
See 3 more Smart Citations
“…Our observation of high GH levels as the most prevalent discordance is in agreement with some (10) but not all studies (7,18). It is, however, problematic to compare discordant values between studies due to pronounced heterogeneity as regards patient populations, GH assays and threshold definitions.…”
Section: Discussionsupporting
confidence: 89%
“…Discordant serum levels of GH and IGF-I are observed in approximately 25% of the patients with acromegaly after treatment in cross-sectional studies (7), but the underlying mechanisms as well as the clinical implications remain unclear. To advance our understanding, we therefore conducted a clinical trial, where SA-treated patients were randomized to being monitored and dosed according to either GH or IGF-I for 12 months.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…At the 3‐6 months postoperative reassessment point, discordance between GH measures and IGF‐1 may present a management dilemma . Close follow‐up with serial measurements over the following year is advocated . The slower decline in IGF‐1 compared to GH seen after surgery may be explained by differences in the half‐life between the 2 hormones and their binding proteins.…”
Section: Discussionmentioning
confidence: 99%